- Home
- TXN vs BMY Comparison
TXN vs BMY Comparison
Compare TXN & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXN
- BMY
- Stock Information
- Founded
- TXN 1930
- BMY 1887
- Country
- TXN United States
- BMY United States
- Employees
- TXN N/A
- BMY N/A
- Industry
- TXN Semiconductors
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- TXN Technology
- BMY Health Care
- Exchange
- TXN Nasdaq
- BMY Nasdaq
- Market Cap
- TXN 137.4B
- BMY 120.5B
- IPO Year
- TXN N/A
- BMY N/A
- Fundamental
- Price
- TXN $172.27
- BMY $46.44
- Analyst Decision
- TXN Hold
- BMY Hold
- Analyst Count
- TXN 27
- BMY 16
- Target Price
- TXN $192.56
- BMY $58.93
- AVG Volume (30 Days)
- TXN 8.7M
- BMY 16.4M
- Earning Date
- TXN 04-23-2025
- BMY 04-24-2025
- Dividend Yield
- TXN 3.16%
- BMY 5.34%
- EPS Growth
- TXN N/A
- BMY N/A
- EPS
- TXN 5.28
- BMY 2.67
- Revenue
- TXN $16,049,000,000.00
- BMY $47,636,000,000.00
- Revenue This Year
- TXN $8.84
- BMY N/A
- Revenue Next Year
- TXN $12.78
- BMY N/A
- P/E Ratio
- TXN $32.63
- BMY $17.39
- Revenue Growth
- TXN N/A
- BMY 4.62
- 52 Week Low
- TXN $139.95
- BMY $39.35
- 52 Week High
- TXN $220.39
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- TXN 59.13
- BMY 30.27
- Support Level
- TXN $159.11
- BMY $48.69
- Resistance Level
- TXN $166.35
- BMY $50.65
- Average True Range (ATR)
- TXN 3.97
- BMY 1.36
- MACD
- TXN 2.42
- BMY 0.04
- Stochastic Oscillator
- TXN 99.09
- BMY 2.66
About TXN Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.